Company Overview and News
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that, on October 1, 2018, the compensation committee of the Company’s board of directors granted 10 new employees options to purchase an aggregate of 63,250 shares of the Company’s common stock with a per share exercise price of $36.90, the closing trading price on the grant date, and restricted stock units for an aggregate of 42,800 shares of the Company’s common stock.
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that three abstracts related to its sickle cell disease (SCD) development programs, including voxelotor, have been accepted for oral presentation during the 46th Annual National Sickle Cell Disease Association of America (SCDAA) Convention in Baltimore, MD, taking place October 10-13, 2018.
2018-09-27 seekingalpha - 2
Many people misinterpreted Global Blood's HOPE part A data as negative just because a secondary endpoint didn't reach "significance".
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2018 Cantor Global Healthcare Conference in New York City on Tuesday, October 2 at 1:05 p.m. Eastern Time.
2018-09-18 seekingalpha - 2
Adam Feuerstein of STAT news released an article last week that was likely responsible for an 8% dip in shares of Global Blood Therapeutics.
2018-09-17 zacks - 2
Investors in Global Blood Therapeutics, Inc. (GBT - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Oct 19, 2018 $40.00 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
2018-09-13 investorplace - 3
Just as Bluebird Bio (NASDAQ:BLUE) started gaining traction in the markets in August, the stock erased all those gains since the start of September. And the month is hardly over. Why did BLUE stock fall 12% last week when the company did not issue any news that would explain what changed, fundamentally?
REGN BLUE DRNA IBB GBT
2018-09-10 seekingalpha - 1
The lead molecule voxelotor (a drug potentially used to treat sickle cell disease) recently posted the strong Phase 2 (HOPE-KIDS 1) data.
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2018 Morgan Stanley Global Healthcare Conference in New York City on Friday, September 14 at 10:30 a.m. Eastern Time.
2018-09-06 globenewswire - 1
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that, on September 4, 2018, the compensation committee of the Company’s board of directors granted five new employees options to purchase an aggregate of 71,000 shares of the Company’s common stock with a per share exercise price of $49.50, the closing trading price on the grant date, and restricted stock units for an aggregate of 48,150 shares of the Company’s common stock.
2018-08-30 sec.gov - 16
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
2018-08-28 investorplace - 5
Are you looking for a post-summer portfolio boost? Look no further. Investment firm Oppenheimer has just released a bullish report highlighting its latest Top Stock Picks for August-September 2018.
ALB TTWO XPO BWA JEF GBT CBAY
2018-03-26 - Asif
Overview Global Blood Therapeutics is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. The company's lead product candidate is voxelotor (previously known as GBT440), an oral, once-daily therapy that modulates hemoglobin’s affinity for oxygen, which the company believe inhibits hemoglobin polymerization in sickle cell disease, or SCD. Global Blood Therapeutics is currently evaluating voxelotor in SCD in a Phase 3 clinical trial in adult and adolescent patients with SCD. In addition, Global Blood Therapeutics is evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase 2a clinical trial of adolescent and pediatric patients with SCD, and in July 2017 the company announced that Global Blood Therapeutics has expanded this open-label trial to include a new single-dose cohort in children aged 6-11. In December 2015, the Food and Dr...
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to GBT / Global Blood Therapeutics, Inc. on message board site Silicon Investor.
as of ET